A biochemical assay for fragment screening & MOA studies

Suffering from a heart attack (myocardial infarction) results in the death of cardiac muscle cells. Therefore, an acute therapy to prevent cardiac muscle death could save lives.

Nemo-Like Kinase (NLK) is a potential cardio-protective drug target. NLK is a highly divergent, atypical member of the mitogen-activated protein kinase (MAPK) group. It lacks some of the features characteristic of MAPKs, making it difficult to study. At Domainex we’ve developed a new biochemical assay that allows fragment screening and mechanism of action (MOA) studies against this target.

Read the full paper